Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2002 Nov;61(Suppl 2):ii2–ii7. doi: 10.1136/ard.61.suppl_2.ii2

Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002)

D Furst, F Breedveld, J Kalden, J Smolen, C Antoni, J Bijlsma, G Burmester, B Cronstein, E Keystone, A Kavanaugh, L Klareskog
PMCID: PMC1766714  PMID: 12379612

Full Text

The Full Text of this article is available as a PDF (109.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Attur M. G., Dave M. N., Stuchin S., Kowalski A. J., Steiner G., Abramson S. B., Denhardt D. T., Amin A. R. Osteopontin: an intrinsic inhibitor of inflammation in cartilage. Arthritis Rheum. 2001 Mar;44(3):578–584. doi: 10.1002/1529-0131(200103)44:3<578::AID-ANR106>3.0.CO;2-7. [DOI] [PubMed] [Google Scholar]
  2. Bathon J. M., Martin R. W., Fleischmann R. M., Tesser J. R., Schiff M. H., Keystone E. C., Genovese M. C., Wasko M. C., Moreland L. W., Weaver A. L. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000 Nov 30;343(22):1586–1593. doi: 10.1056/NEJM200011303432201. [DOI] [PubMed] [Google Scholar]
  3. Braun J., Brandt J., Listing J., Zink A., Alten R., Golder W., Gromnica-Ihle E., Kellner H., Krause A., Schneider M. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet. 2002 Apr 6;359(9313):1187–1193. doi: 10.1016/s0140-6736(02)08215-6. [DOI] [PubMed] [Google Scholar]
  4. Bresnihan B., Alvaro-Gracia J. M., Cobby M., Doherty M., Domljan Z., Emery P., Nuki G., Pavelka K., Rau R., Rozman B. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 1998 Dec;41(12):2196–2204. doi: 10.1002/1529-0131(199812)41:12<2196::AID-ART15>3.0.CO;2-2. [DOI] [PubMed] [Google Scholar]
  5. Cohen Stanley, Hurd Eric, Cush John, Schiff Michael, Weinblatt Michael E., Moreland Larry W., Kremer Joel, Bear Moraye B., Rich William J., McCabe Dorothy. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002 Mar;46(3):614–624. doi: 10.1002/art.10141. [DOI] [PubMed] [Google Scholar]
  6. Dayer Jean-Michel, Bresnihan Barry. Targeting interleukin-1 in the treatment of rheumatoid arthritis. Arthritis Rheum. 2002 Mar;46(3):574–578. doi: 10.1002/art.10168. [DOI] [PubMed] [Google Scholar]
  7. Elliott M. J., Maini R. N., Feldmann M., Kalden J. R., Antoni C., Smolen J. S., Leeb B., Breedveld F. C., Macfarlane J. D., Bijl H. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet. 1994 Oct 22;344(8930):1105–1110. doi: 10.1016/s0140-6736(94)90628-9. [DOI] [PubMed] [Google Scholar]
  8. Elliott M. J., Maini R. N., Feldmann M., Long-Fox A., Charles P., Bijl H., Woody J. N. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet. 1994 Oct 22;344(8930):1125–1127. doi: 10.1016/s0140-6736(94)90632-7. [DOI] [PubMed] [Google Scholar]
  9. Elliott M. J., Maini R. N., Feldmann M., Long-Fox A., Charles P., Katsikis P., Brennan F. M., Walker J., Bijl H., Ghrayeb J. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. 1993 Dec;36(12):1681–1690. doi: 10.1002/art.1780361206. [DOI] [PubMed] [Google Scholar]
  10. Furst D. E., Keystone E., Maini R. N., Smolen J. S. Recapitulation of the round-table discussion--assessing the role of anti-tumour necrosis factor therapy in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 1999 Nov;38 (Suppl 2):50–53. [PubMed] [Google Scholar]
  11. Garrison L., McDonnell N. D. Etanercept: therapeutic use in patients with rheumatoid arthritis. Ann Rheum Dis. 1999 Nov;58 (Suppl 1):I65–I69. doi: 10.1136/ard.58.2008.i65. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hanauer S. B. Review article: safety of infliximab in clinical trials. Aliment Pharmacol Ther. 1999 Sep;13 (Suppl 4):16–38. doi: 10.1046/j.1365-2036.1999.00027.x. [DOI] [PubMed] [Google Scholar]
  13. Harriman G., Harper L. K., Schaible T. F. Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNFalpha treatment. Ann Rheum Dis. 1999 Nov;58 (Suppl 1):I61–I64. doi: 10.1136/ard.58.2008.i61. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Jarvis B., Faulds D. Etanercept: a review of its use in rheumatoid arthritis. Drugs. 1999 Jun;57(6):945–966. doi: 10.2165/00003495-199957060-00014. [DOI] [PubMed] [Google Scholar]
  15. Jiang Y., Genant H. K., Watt I., Cobby M., Bresnihan B., Aitchison R., McCabe D. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum. 2000 May;43(5):1001–1009. doi: 10.1002/1529-0131(200005)43:5<1001::AID-ANR7>3.0.CO;2-P. [DOI] [PubMed] [Google Scholar]
  16. Jones R. E., Moreland L. W. Tumor necrosis factor inhibitors for rheumatoid arthritis. Bull Rheum Dis. 1999;48(3):1–4. [PubMed] [Google Scholar]
  17. Kavanaugh A. F. Anti-tumor necrosis factor-alpha monoclonal antibody therapy for rheumatoid arthritis. Rheum Dis Clin North Am. 1998 Aug;24(3):593–614. doi: 10.1016/s0889-857x(05)70028-4. [DOI] [PubMed] [Google Scholar]
  18. Keane J., Gershon S., Wise R. P., Mirabile-Levens E., Kasznica J., Schwieterman W. D., Siegel J. N., Braun M. M. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001 Oct 11;345(15):1098–1104. doi: 10.1056/NEJMoa011110. [DOI] [PubMed] [Google Scholar]
  19. Lipsky P. E., van der Heijde D. M., St Clair E. W., Furst D. E., Breedveld F. C., Kalden J. R., Smolen J. S., Weisman M., Emery P., Feldmann M. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000 Nov 30;343(22):1594–1602. doi: 10.1056/NEJM200011303432202. [DOI] [PubMed] [Google Scholar]
  20. Lovell D. J., Giannini E. H., Reiff A., Cawkwell G. D., Silverman E. D., Nocton J. J., Stein L. D., Gedalia A., Ilowite N. T., Wallace C. A. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med. 2000 Mar 16;342(11):763–769. doi: 10.1056/NEJM200003163421103. [DOI] [PubMed] [Google Scholar]
  21. Maini R. N., Breedveld F. C., Kalden J. R., Smolen J. S., Davis D., Macfarlane J. D., Antoni C., Leeb B., Elliott M. J., Woody J. N. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998 Sep;41(9):1552–1563. doi: 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W. [DOI] [PubMed] [Google Scholar]
  22. Markham A., Lamb H. M. Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs. 2000 Jun;59(6):1341–1359. doi: 10.2165/00003495-200059060-00010. [DOI] [PubMed] [Google Scholar]
  23. Mease P. J., Goffe B. S., Metz J., VanderStoep A., Finck B., Burge D. J. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000 Jul 29;356(9227):385–390. doi: 10.1016/S0140-6736(00)02530-7. [DOI] [PubMed] [Google Scholar]
  24. Mohan N., Edwards E. T., Cupps T. R., Oliverio P. J., Sandberg G., Crayton H., Richert J. R., Siegel J. N. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum. 2001 Dec;44(12):2862–2869. doi: 10.1002/1529-0131(200112)44:12<2862::aid-art474>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  25. Moreland L. W., Margolies G., Heck L. W., Jr, Saway A., Blosch C., Hanna R., Koopman W. J. Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis. J Rheumatol. 1996 Nov;23(11):1849–1855. [PubMed] [Google Scholar]
  26. Moreland L. W., Schiff M. H., Baumgartner S. W., Tindall E. A., Fleischmann R. M., Bulpitt K. J., Weaver A. L., Keystone E. C., Furst D. E., Mease P. J. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med. 1999 Mar 16;130(6):478–486. doi: 10.7326/0003-4819-130-6-199903160-00004. [DOI] [PubMed] [Google Scholar]
  27. Rozenbaum M., Rosner I., Portnoy E. Remission of Behçet's syndrome with TNFalpha blocking treatment. Ann Rheum Dis. 2002 Mar;61(3):283–284. doi: 10.1136/ard.61.3.283-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Sfikakis P. P., Theodossiadis P. G., Katsiari C. G., Kaklamanis P., Markomichelakis N. N. Effect of infliximab on sight-threatening panuveitis in Behçet's disease. Lancet. 2001 Jul 28;358(9278):295–296. doi: 10.1016/s0140-6736(01)05497-6. [DOI] [PubMed] [Google Scholar]
  29. Shekelle P. G., Woolf S. H., Eccles M., Grimshaw J. Clinical guidelines: developing guidelines. BMJ. 1999 Feb 27;318(7183):593–596. doi: 10.1136/bmj.318.7183.593. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Steinfeld S. D., Demols P., Salmon I., Kiss R., Appelboom T. Infliximab in patients with primary Sjögren's syndrome: a pilot study. Arthritis Rheum. 2001 Oct;44(10):2371–2375. doi: 10.1002/1529-0131(200110)44:10<2371::aid-art401>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  31. Wolfe F., Pincus T., O'Dell J. Evaluation and documentation of rheumatoid arthritis disease status in the clinic: which variables best predict change in therapy. J Rheumatol. 2001 Jul;28(7):1712–1717. [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES